Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Gilead Sciences 7.803, Vertex Pharmaceuticals 3.334.
Gilead Sciences vs Vertex Pharmaceuticals: Revenue Comparison
Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) are peers in Healthcare. Gilead Sciences reported revenue of $7.8B as of Q2 2026, compared with $3.3B for Vertex Pharmaceuticals. Gilead Sciences leads on revenue.
Gilead Sciences's gross margin is 79.8% versus 85.3% for Vertex Pharmaceuticals. Gilead Sciences's net margin is -134.5% versus 33.0% for Vertex Pharmaceuticals.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Gilead Sciences, Vertex Pharmaceuticals.| Metric | Gilead Sciences | Vertex Pharmaceuticals |
|---|---|---|
| Market Cap | - | - |
| Revenue | $7.80B | $3.33B |
| Cost of Revenue | $1.58B | $489.00M |
| Gross Profit | $6.22B | $2.85B |
| Operating Income | $-10.39B | $1.25B |
| Net Income | $-10.50B | $1.10B |
| R&D Expense | $1.76B | $994.00M |
| Earnings Per Share | -$8.45 | $4.31 |
| Gross Margin | 79.8% | 85.3% |
| Operating Margin | -133.2% | 37.4% |
| Net Profit Margin | -134.5% | 33.0% |
| Free Cash Flow | $3.69B | $1.01B |
| Cumulative Free Cash Flow | $155.83B | $17.24B |
| Operating Cash Flow | $3.57B | $1.13B |
| Cash & Equivalents | $3.18B | $6.14B |